View Post

Tyme Technologies Begins Cancer Metabolism-Based Therapy Trial in Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Tyme Technologies said on Monday it has dosed the first patient in its Phase II OASIS trial of SM-88 in previously treated metastatic hormone receptor (HR)-positive HER2-negative breast cancer patients. The investigator-initiated study at Georgetown University will initially enroll 30 patients with metastatic HR-positive HER2-negative breast cancer who have previously received at least two lines …

View Post

Extended Letrozole Reduced Recurrence Risk in Postmenopausal Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Mike Bassett From: medpagetoday.com 5 years of the aromatase inhibitor improved disease-free survival vs 2-3 years Five years of extended treatment with the aromatase inhibitor letrozole significantly improved disease-free survival (DFS) compared with the standard duration of 2 to 3 years in postmenopausal patients with breast cancer who had already received 2 to 3 years of tamoxifen, according to …

View Post

Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021

In In The News by Barbara Jacoby

From: biospace.com Phase 2a Tolerability and Efficacy Data Supports Further Clinical Development of Samuraciclib in Combination with Fulvestrant in HR+, HER2- Breast Cancer Previously Treated with a CDK4/6 Inhibitor Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today presented encouraging initial clinical data on samuraciclib (CT-7001), an oral and first-in-class inhibitor of CDK7, at the 2021 …

View Post

PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC

In Clinical Studies News by Barbara Jacoby

Source: PharmAbcine From: prnewswire.com PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has received Human Research Ethics Committee (HREC) clearance to commence the Phase II combination trial of olinvacimab, PharmAbcine’s anti-VEGFR2 antibody, and KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 molecule, for the treatment of metastatic Triple-Negative Breast Cancer (mTNBC) in …

View Post

HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer

In Clinical Studies News by Barbara Jacoby

Source: HUTCHMED (China) Limited From: globenewswire.com HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients with advanced triple negative breast cancer (“TNBC”) or advanced endometrial cancer (“EC”) in the U.S. The first patient was dosed on August 24, 2021. This trial is to explore the potential for …

View Post

Leronlimab Provides a Significant Survival Benefit in Metastatic Triple-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Ariana Pelosci From: cancernetwork.com Leronlimab yielded a notable increase in overall survival and progression-free survival in patients with metastatic triple-negative breast cancer. The use of leronlimab (PRO 140) in patients with metastatic triple-negative breast cancer (mTNBC) resulted in a notable increase in both overall survival (OS) and progression-free survival (PFS), according to a press release on a phase 1b/2 …

View Post

New clinical trial investigates aspirin as part of new treatment for triple negative breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Breast Cancer Now From: news-medical.net An innovative new study is trialing whether giving aspirin, commonly used as pain relief, alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer. Used in combination, aspirin and avelumab could potentially stop people dying from this disease. The clinical trial is being funded by the Breast Cancer Now Catalyst …

View Post

Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 Randomized Clinical Trial Assessing Efficacy of Oral Lasofoxifene Versus Intramuscular Fulvestrant

In In The News by Barbara Jacoby

Source: Sermonix Pharmaceuticals LLC From: globenewswire.com The study enrolled 100 patients who have ER+/HER2- breast cancer with an ESR1 mutation, with topline data expected in first half of 2022 Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it has completed enrollment in its Phase 2 randomized …

View Post

Enhertu improves survival in Phase III breast cancer trial

In Clinical Studies News by Barbara Jacoby

From: europeanpharmaceuticalreview.com Enhertu (trastuzumab deruxtecan) significantly improved survival in the DESTINY-Breast03 Phase III head-to-head trial against trastuzumab emtansine. Positive high-level results from the head-to-head DESTINY-Breast03 Phase III trial has shown that Enhertu (trastuzumab deruxtecan) demonstrates superiority over trastuzumab emtansine (T-DM1) in treating HER2-positive metastatic breast cancer. Enhertu is an HER2-directed antibody drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo, …

View Post

CDK4/6 Inhibitors Continue to Build Traction in Early-Stage ER+/HER2- Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: onclive.com Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor (ER)–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice, explained Joyce A. O’Shaughnessy, MD, during a presentation at the 20th Annual International Congress on …